EC Number | Application | Comment | Organism |
---|---|---|---|
3.4.21.89 | medicine | inhibition of enzyme by arylomycin A-C16 results in an insufficient flux of proteins through the secretion pathway leading to mislocalization of proteins. Inhibition results in synergistic sensitivity of cells when combined with an aminoglycoside. Antibiotics tetracycline, erythromycin, and vancomycin each interact additively with arylomycin A-C16, while rifampin and trimethoprim show pronounced antagonism | Staphylococcus aureus |
3.4.21.89 | medicine | inhibition of enzyme by arylomycin A-C16 results in an insufficient flux of proteins through the secretion pathway leading to mislocalization of proteins. Inhibition results in synergistic sensitivity of cells when combined with an aminoglycoside. No significant interactions are observed between arylomycin A-C16 and erythromycin, polymyxin B, trimethoprim, or ciprofloxacin. Arylomycin A-C16 shows mild synergism with cephalexin, pronounced synergism with rifampin and gentamicin, and antagonism with the translational inhibitor tetracycline | Escherichia coli |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.4.21.89 | arylomycin A-C16 | inhibition of enzyme results in an insufficient flux of proteins through the secretion pathway leading to mislocalization of proteins. Inhibition results in synergistic sensitivity when combined with an aminoglycoside | Escherichia coli | |
3.4.21.89 | arylomycin A-C16 | inhibition of enzyme results in an insufficient flux of proteins through the secretion pathway leading to mislocalization of proteins. Inhibition results in synergistic sensitivity when combined with an aminoglycoside | Staphylococcus aureus |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.4.21.89 | Escherichia coli | - |
- |
- |
3.4.21.89 | Staphylococcus aureus | - |
- |
- |